bone development News
-
Synergy Biomedical Launches BIOSPHERE® Flex SP Extremities, Synthetic Bioactive Bone Graft.
Synergy Biomedical, LLC, a developer of innovative biomaterial products, today announced the launching of BIOSPHERE® FLEX SP EXTREMITIES, Synthetic Bioactive Bone Graft. Using Synergy’s proprietary BIOSPHERE® Technology, BIOSPHERE® FLEX SP Extremities is a sheet putty composed of innovative spherical bioactive glass granules combined with a porous collagen/sodium hyaluronate ...
-
LaunchPad Medical Rebrands as RevBio and Launches an Updated Website
Executives from LaunchPad Medical, Inc. announced that the company has rebranded. Its new name, RevBio, was chosen since it more accurately portrays the objective of developing its revolutionary Tetranite® bone adhesive biomaterial platform. The company has also adapted a tag line "Transforming Bone Repair" which better defines the company's musculoskeletal focus in developing products for ...
By RevBio Inc.
-
Isto Biologics acquires TheraCell, adding additional novel products to help patients heal faster.
Isto Biologics, a leader in surgical-based, orthobiologic regeneration technologies and cell-based therapies, announced today that it has acquired TheraCell, Inc., a California-based regenerative medicine company. The acquisition will strengthen Isto’s focus on offering extraordinary solutions for surgical and clinical care procedures within spine, orthopedics, and sports medicine. ...
-
Bone Therapeutics signs definitive subscription agreement for a maximum of EUR 5M convertible bonds facility with ABO
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics, today announces that it has signed the definitive subscription agreement for a maximum EUR 5 million convertible bonds (CBs) facility arranged by ABO Securities, through its affiliated entity Global Tech Opportunities 15. The proceeds of the financing will contribute to ...
-
NuShores Biosciences receives new contract for intelligent manufacturing automation of NuCress medical devices
Little Rock, AR – NuShores Biosciences LLC has won a 3-year, $2.8M contract from the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium associated with the U.S. Army Medical Research and Development Command. The contract will enable NuShores to develop intelligent automated production of its NuCress™ bone void filler scaffold products using ...
-
ZetaMet™ Receives Breakthrough Device Designation from U.S. Food and Drug Administration (FDA) for Treatment of Metastatic Bone Cancers
The technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Zetagen Therapeutics is developing the therapy for patients living with metastatic bone lesions and other osteologic conditions The Company is targeting its first human clinical trial for metastatic bone lesions to begin in early 2022 Zetagen Therapeutics, a private, ...
-
Synergy Biomedical Announces Publication of Core Scientific Study on Its BioSphere® Bone Graft Technology
Synergy Biomedical, LLC, a developer of innovative bone graft products for spine and orthopedic surgery, announced the publication of a basic science study describing the findings and scientific strategies of controlling the bone formation response of bioactive glass. This study was conducted by Synergy’s founder, Mark Borden Ph.D. and a team of clinical and basic science collaborators, and ...
-
Stem Cell Agency Awards Almost $4 Million to Develop a Treatment for Spinal Degeneration
Today the governing Board of the California Institute for Regenerative Medicine (CIRM) awarded $3.9 million to Ankasa Regenerative Therapeutics for a promising approach to treat a degenerative condition that can cause chronic, progressive back pain. As we get older, the bones, joints and ligaments in our back become weak and less able to hold the spinal column in alignment. As a result, an ...
-
Testing Your Bone Density for Osteoporosis Awareness Month
Testing your bone density may not be a usual task on your priority list, but May serves as National Osteoporosis Month and can serve as a friendly reminder to check your bone density. Osteoporosis is a skeletal condition that affects far more women than it does men. Low bone mass puts you more at risk for osteoporosis, so regular and early bone density testing can greatly help you. Beam Med is a ...
By BeamMed Inc.
-
KLISBio to unveil cutting-edge silk-based technology platform at 2022 Digital RESI Conference
Milan, Italy (March 21, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance 2022 Digital RESI. The conference will be held March 22-24, 2022 through a virtual platform. KLISBio’s designated attendee to Digital RESI Conference is Gabriele Grecchi, CEO ...
By KLISBio
-
Molecular Matrix, Inc. Forms Strategic Alliance with Philosys Healthcare
On August 7, 2019, Molecular Matrix, Inc. (MMI) announced the signing of a Memorandum of Understanding (MOU) with Philosys Healthcare Co., Ltd., a biomedical distribution and manufacturing company based in Seongnam, South Korea. MMI is a biotechnology company that began as a startup at UC Davis, and after more than 10 years of research and development has created a scaffold for bone tissue ...
-
KLISBio to share innovative tissue-engineered technology at LSI 2022 Emerging MedTech Summit
Milan, Italy (March 14, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to LSI 2022 Emerging MedTech Summit. LSI Annual Meeting will be held March 15 -18, 2022 in Dana Point – CA. KLISBio’s designated attendee to LSI Emerging MedTech Summit ...
By KLISBio
-
KLISBio to share innovative tissue-engineered technology at BIO Partnering with JP Morgan
Among the best of new innovations in life sciences and biomedicine being unveiled to investors and healthcare leaders at JP Morgan’s BIO Partnering conference this month is KLISBio’s silk-based biomedical technology. Among the company’s developing portfolio of products is SILKBridge®, a first-to-market, silk-based graft for peripheral nerve repair, which is anticipated ...
By KLISBio
-
KLISBio to feature engineered silk innovation at AAHS 2022
With the profound impact on patients’ quality of life, peripheral nerve injuries remain at the forefront of treatment challenges for orthopedic surgeons. That’s a driving force behind KLISBio’s SILKBridge®, a first-to-market solution for peripheral nerve repair. KLISBio will introduce SILKBridge® to attendees at the American Association for Hand Surgeons Annual Meeting ...
By KLISBio
-
KLISBio to share its leading-edge silk-based technology platform at 2022 AAOS Annual Meeting
Milan, Italy (March 23, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance 2022 American Academy of Orthopaedic Surgeons Annual Meeting. The event will be held March 22-26 in Chicago -IL. KLISBio’s designated attendee to 2022 AAOS Congress is Jason ...
By KLISBio
-
KLISBio to feature engineered silk innovation at Biotech Showcase
Investors keen to get involved with a company on the forefront of human tissue regeneration will be interested to visit with KLISBio, an international medtech company bringing its silk-based biomedical technology and the first of their products, SILKBridge®, to the Biotech Showcase Jan. 10-19. KLISBio is leading a revolution in restorative surgical procedures using engineered silk ...
By KLISBio
-
KLISBio to present SILKBridge for peripheral nerve repair and its innovative silk-based tissue-engineered technology platform at 2022 Bio€quity Europe
Milan, Italy (May 11, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to 2022 Bio€quity Europe. 2022 Bio€quity Europe will be held May 16 -18, 2022 in Milan – Italy. Antonio Alessandrino, CTO and Founder of KLISBio, will be presenting on ...
By KLISBio
-
Bone Therapeutics announces closing of private placement
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces the closing of the private placement announced on 3 December 2021, with existing and new institutional investors having purchased 4,832,352 new shares at an issue price of EUR 0.68 per share resulting in gross proceeds of approximately ...
-
Bone Therapeutics to host Annual General Meeting and Extraordinary General Meeting on 8 June 2022
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics, invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the Annual General Meeting to be held on Wednesday 8 June 2022 as from 4:00 pm CEST, at Rue Granbonpré 11, Building H, 1435 ...
-
KLISBio to disclose state-of-the-art tissue-engineered technology platform at 2022 CG Musculoskeletal Conference
Milan, Italy (March 22, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to 2022 CG Musculoskeletal Conference. Ahead of the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting March 22-26, 2022 in Chicago, Canaccord Genuity will host its CG ...
By KLISBio
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you